ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1118

Role of the Chemokine Receptor CXCR3 in the Function of Regulatory B Cells in Patients with SLE

Shun-ichiro Ota1,2, Hiroaki Niiro3, Naoko Ueki2,4, Yuri Hirosaki2, Hirofumi Tsuzuki2, Siamak Jabbarzadeh-Tabrizi2, Tsuyoshi Nakayama2, Koji Mishima2, Ayako Takaki2, Hiroki Mitoma2, Mitsuteru Akahoshi2, Yojiro Arinobu2, Hiroshi Tsukamoto2 and Koichi Akashi2, 1Department of Rheumatology, Internal medicine and connective tissue disorders, Shimonoseki City Hospital, Shimonoseki, Japan, 2Department of Medicine and Biosystemic Science, Kyushu University Graduate School of Medical Sciences, Fukuoka, Japan, 3Clinical Education Center, Kyushu University Hospital, Fukuoka, Japan, 4Division of Nephrology and Rheumatology, Fukuoka University, Fukuoka, Japan

Meeting: 2015 ACR/ARHP Annual Meeting

Date of first publication: September 29, 2015

Keywords: B cells, Chemokine Receptors, regulatory cells and systemic lupus erythematosus (SLE)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 9, 2015

Title: B cell Biology and Targets in Rheumatolid Arthritis and other Autoimmune Disease Poster

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: The emerging application of B-cell directed therapies in autoimmune diseases has led to the discovery of a novel B cell population, referred to as regulatory B cells (Bregs), that exerts regulatory functions via IL-10 production. We previously showed that human Bregs are strongly induced in IgM-memory (IgMM) B cell subsets following TLR9 stimulation and Breg functions are impaired due to attenuated induction of Blimp1 in systemic lupus erythematosus (SLE). It remains, however, largely elusive about the underlying mechanisms of this phenomenon in SLE patients. Given a critical role of C-X-C chemokine receptor type 3 (CXCR3) in inflammation, in the present study we have tested whether the migratory potential of Bregs is associated with their regulatory functions in healthy donors and patients with SLE.

Methods: Human B cell subsets in healthy donors and patients with SLE were enriched by cell sorting and subjected to the analysis of gene and protein expression by quantitative PCR, ELISA and flow cytometry.

Results: CXCR3, the chemokine receptor for CXCL10 and CXCL11, is predominantly expressed on T helper type 1 cells, a T-cell subset which plays a pivotal role in the initiation and perpetuation of inflammation. In human B cells CXCR3 was mainly expressed on memory subsets. We first tested Breg potential of CXCR3+ and CXCR3- IgMM B cells in healthy donors, and found that both subsets exhibited comparable potential in IL-10 production, suggesting that CXCR3 expression itself does not affect Breg function. Intriguingly, however, stimulation of CXCL10 and CXCL11 exerted inhibitory and stimulatory effects, respectively, on IL-10 production along with alteration of Blimp1 expression. Consistent with previous findings that the serum levels of CXCL10 are elevated in patients with SLE, CXCR3+ IgMM B cells in patients exhibited decreased potential in IL-10 expression compared with this subset in healthy donors, suggesting that aberrant expression of chemokine ligands is associated with crippled Breg function in patients with SLE.

Conclusion: Together, these findings uncover not only a new aspect of regulation of Breg function in humans, but also a novel clue to the revitalization of Bregs for the treatment of SLE.


Disclosure: S. I. Ota, None; H. Niiro, None; N. Ueki, None; Y. Hirosaki, None; H. Tsuzuki, None; S. Jabbarzadeh-Tabrizi, None; T. Nakayama, None; K. Mishima, None; A. Takaki, None; H. Mitoma, None; M. Akahoshi, None; Y. Arinobu, None; H. Tsukamoto, None; K. Akashi, None.

To cite this abstract in AMA style:

Ota SI, Niiro H, Ueki N, Hirosaki Y, Tsuzuki H, Jabbarzadeh-Tabrizi S, Nakayama T, Mishima K, Takaki A, Mitoma H, Akahoshi M, Arinobu Y, Tsukamoto H, Akashi K. Role of the Chemokine Receptor CXCR3 in the Function of Regulatory B Cells in Patients with SLE [abstract]. Arthritis Rheumatol. 2015; 67 (suppl 10). https://acrabstracts.org/abstract/role-of-the-chemokine-receptor-cxcr3-in-the-function-of-regulatory-b-cells-in-patients-with-sle/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2015 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/role-of-the-chemokine-receptor-cxcr3-in-the-function-of-regulatory-b-cells-in-patients-with-sle/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology